Skip to main content
Top
Published in: Investigational New Drugs 2/1999

01-05-1999

Anti-Angiogenic Activity of Selected Receptor Tyrosine Kinase Inhibitors, PD166285 and PD173074: Implications for Combination Treatment with Photodynamic Therapy

Authors: Charles J. Dimitroff, Wayne Klohs, Amarnath Sharma, Paula Pera, Denise Driscoll, Jean Veith, Randall Steinkampf, Mel Schroeder, Sylvester Klutchko, Adam Sumlin, Barbara Henderson, Thomas J. Dougherty, Ralph J. Bernacki

Published in: Investigational New Drugs | Issue 2/1999

Login to get access
Metadata
Title
Anti-Angiogenic Activity of Selected Receptor Tyrosine Kinase Inhibitors, PD166285 and PD173074: Implications for Combination Treatment with Photodynamic Therapy
Authors
Charles J. Dimitroff
Wayne Klohs
Amarnath Sharma
Paula Pera
Denise Driscoll
Jean Veith
Randall Steinkampf
Mel Schroeder
Sylvester Klutchko
Adam Sumlin
Barbara Henderson
Thomas J. Dougherty
Ralph J. Bernacki
Publication date
01-05-1999
Publisher
Kluwer Academic Publishers
Published in
Investigational New Drugs / Issue 2/1999
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI
https://doi.org/10.1023/A:1006367032156

Other articles of this Issue 2/1999

Investigational New Drugs 2/1999 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine